Nagata Toshihiko, van Vliet Irene, Yamada Hisashi, Kataoka Kouhei, Iketani Toshiya, Kiriike Nobuo
Department of Neuropsychiatry, Osaka City University Medical School, Osaka, Japan.
Depress Anxiety. 2006;23(3):168-74. doi: 10.1002/da.20153.
The taijin kyofusho (TKS) offensive subtype is thought to be a culture-bound syndrome similar to social anxiety disorder (SAD). In Western countries, such patients would be diagnosed as having delusional disorder, somatic subtype, or body dysmorphic disorder. Recently, open trials for the TKS offensive subtype and a randomized controlled trial for body dysmorphic disorder demonstrated that selective serotonin reuptake inhibitors (SSRIs) might be as effective in TKS as in SAD. This study investigated the efficacy of the SSRI paroxetine in patients with the TKS offensive subtype, both on anxiety and fears, as well as insight. This study was a 12-week open trial using paroxetine in 22 patients with TKS. Subjects were diagnosed based on the original diagnostic criteria for the TKS offensive subtype. Insight regarding TKS symptoms was assessed by the 11th supplement subscale "Insight into obsessions and compulsions" of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The Liebowitz Social Anxiety Scale (LSAS), the Beck Depression Inventory (BDI), the State-Trait Anxiety Inventory (STAI), Rosenberg's Self-Esteem Scale, and the Interpersonal Distrust subscale of the Eating Disorder Inventory were also administered. Offensive anxiety was assessed by the original TKS offensive anxiety subscale (0-3 points). The primary efficacy variable was the Clinical Global Impression scale (CGI) global improvement item. Nineteen patients completed the study. Forty-seven percent (9/19) were responders to the drug treatment (scoring 2 or less on the CGI). Last observation carried forward (LOCF) analysis (N=22) demonstrated a statistically significant reduction in LSAS total score and offensive anxiety in TKS, and the insight scale score of the Y-BOCS also significantly improved. Interpersonal distrust showed a trend toward improvement.
恐人症(TKS)的攻击亚型被认为是一种与社交焦虑障碍(SAD)类似的文化相关综合征。在西方国家,这类患者会被诊断为患有妄想障碍、躯体亚型或躯体变形障碍。最近,针对TKS攻击亚型的开放试验以及针对躯体变形障碍的随机对照试验表明,选择性5-羟色胺再摄取抑制剂(SSRIs)对TKS的疗效可能与对SAD的疗效相同。本研究调查了SSRI帕罗西汀对TKS攻击亚型患者焦虑、恐惧以及自知力的疗效。本研究是一项为期12周的开放试验,对22例TKS患者使用了帕罗西汀。根据TKS攻击亚型的原始诊断标准对受试者进行诊断。通过耶鲁-布朗强迫量表(Y-BOCS)的第11个补充分量表“对强迫观念和强迫行为的自知力”评估对TKS症状的自知力。还使用了利博维茨社交焦虑量表(LSAS)、贝克抑郁量表(BDI)、状态-特质焦虑量表(STAI)、罗森伯格自尊量表以及进食障碍量表的人际不信任分量表。通过原始的TKS攻击焦虑分量表(0-3分)评估攻击焦虑。主要疗效变量为临床总体印象量表(CGI)的总体改善项目。19例患者完成了研究。47%(9/19)的患者对药物治疗有反应(CGI评分≤2分)。末次观察结转(LOCF)分析(N=22)显示,TKS患者的LSAS总分和攻击焦虑有统计学意义的降低,Y-BOCS的自知力量表评分也显著改善。人际不信任有改善趋势。